The endTB (Expand New Drug Markets for TB) consortium consists of three NGOs: Partners In Health (PIH), Médecins Sans Frontières (MSF) and Interactive Research and Development (IRD). Funded by Unitaid, the objective of endTB is to promote better and safer MDR-TB treatment regimens. The endTB Observational Study currently has sites in 17 countries. In each country, sites enroll patients on treatment with bedaquiline and delamanid according to National TB Program guidelines, while collecting clinical and bacteriological data related to efficacy and safety.
endTB presentations from the WHO Global Consultation on Transition Towards New and Better Treatments for MDR-TB, Geneva, November 2018
Researchers from endTB participated in the WHO Global Consortium to share the study’s implementation practices and updated results, providing evidence to support the transition, operationalization, and scale-up of new MDR-TB guidelines.
The following presentations are for individual reference, on behalf of the endTB study. Data is not yet published or peer reviewed.
This MSF Access Campaign report – now in its fifth edition – analyses the barriers and factors affecting access to treatment regimens for drug-resistant tuberculosis (DR-TB), including new and repurposed drugs.
We provide detailed pricing profiles of key DR-TB drugs, using manufacturer responses to standardised questionnaires and the Global TB Drug Facility website.
This report was produced with endTB's support.
Bedaquiline- and delamanid- containing regimens achieve excellent interim treatment response without safety concerns - endTB interim analysis (EN / ES / RUS)
This guide is designed to give guidance to the endTB Project site on the use of new TB drugs bedaquiline and delamanid.
It is intended to be a resource for physicians and other health care professionals involved in the endTB project.
The clinical guide is available in English, Russian, Spanish and French.
The Patent Opposition Database is a site that allows civil society to share resources and learn about the tools needed to oppose the application or granting of unwarranted patents on medicines. The site contains a wealth of information on existing patent oppositions, patent applications, patent office decisions, court cases and other vital documents that will inform users own preparation for filing an opposition by sharing these resources and the experience of others.
Although it can be prevented and successfully treated, tuberculosis (TB) is the world’s deadliest infectious disease: in 2015, 1.8 million people died from it. While there have been substantial and important innovations in the fight against TB, including faster, more accurate diagnostic tests and the first new medicines in nearly 50 years, deadly gaps remain in implementing and providing access to these advances.
The endTB Medical Committee formulates recommendations for off-label and compassionate use of the new anti-TB drugs for M(X)DR-TB.
It provides advice to any MSF, PIH and IRD projects for individual patient’s management on a case-by-case basis in answer to requests initiated by clinicians from the projects.
For more information, please download the terms of reference.
An overview of MSF’s programmatic use and clinical research with new TB treatment regimens.